Top 5 Medical Stocks To Buy Right Now

The pain in her legs was so unbearable that she couldn’t muster one more step… let alone the dozen or so needed to make it to her sorority just down the street. She had to call a friend to pick her up.

Nicole Labonte didn’t know what was happening. But this was the first sign that something was clearly wrong, and she needed to see a doctor immediately. A trip to the health center revealed that her blood pressure was astronomically high. After several tests, they finally diagnosed Nicole with a rare vascular disease called Takayasu arteritis, which causes inflammation of the largest blood vessel in the body, the aorta, and its branches.

Vascular diseases, like the one Nicole was diagnosed with, can be difficult to detect. Diseases can appear anywhere in the body in many different forms. In fact, John Hopkins Medical Center estimates that 78 million Americans have the most common form… high blood pressure.

Top 5 Medical Stocks To Buy Right Now: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma
  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

Top 5 Medical Stocks To Buy Right Now: Insperity, Inc.(NSP)

Advisors’ Opinion:

  • [By Lee Jackson]

    Insperity Inc. (NYSE: NSP) also had a large-scale seller on the desk, and it was another well-known hedge fund. Value Act, which also serves as a director at the company, sold a total of 226,000 shares of the stock at prices that ranged from $71.22 to $72.41. The total for the sale was set at $16 million.Insperity provides an array of human resources and business solutions to enhance business performance for small and medium-sized businesses in the United States. The shares closed the day on Friday at $71.85.

Top 5 Medical Stocks To Buy Right Now: Adeptus Health Inc.(ADPT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Adeptus Health Inc (NYSE: ADPT) were down around 30 percent to $1.30. Medical Properties Trust disclosed that it has agreed in principle with Deerfield Management to restructuring in bankruptcy to Adeptus Health.

  • [By Lisa Levin]

    Adeptus Health Inc (NASDAQ: ADPT) shares dropped 66 percent to $9.09 after the company posted downbeat quarterly results and lowered its FY16 EBITDA outlook.

Top 5 Medical Stocks To Buy Right Now: L'Or茅al S.A. (LRLCY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Absent any debt repayment via cash flow YTD in 2017, Valeant has long term Debt of approx. $28.65B after the closing of the skincare assets to L’Oreal (OTCPK:LRLCY), and slightly under $28 Billion when the Dendreon sale to Sanpower closes and they use those proceeds to pay down debt.

  • [By WWW.THESTREET.COM]

    GLP’s customers include Walmart (WMT) , Unilever (UL) , JD.com (JD) , Adidas (ADDYY) , Estee Lauder (EL) and L’Oreal (LRLCY) .

    The S$3.38 offer price represents 81% premium over its 12-month volume weighted average price and a 25% premium over its last full trading day before the announcement.

  • [By SEEKINGALPHA.COM]

    Besides these American and Swiss titans, Unilever also faces global competition from French cosmetics giant L’Oreal (OTCPK:LRLCY) (OTCPK:LRLCF), from Colgate-Palmolive (NYSE:CL) and from Reckitt Benckiser , in the home and personal care spaces, as well as from Danone (OTCQX:DANOY), Mondelez (NASDAQ:MDLZ) and from KraftHeinz (NASDAQ:KHC) in the Big Food arena.

  • [By SEEKINGALPHA.COM]

    Valeant’s other sale of CeraVe and several other skin care assets to L’Oreal (OTCPK:LRLCY) for $1.3B is even more spectacular. It is almost eight times the $150M Valeant spent to buy these assets between 2008 and 2012 according to this source. “Lost value” indeed. The sales price is ~20x EBITDA, showing that Valeant has received a very good price for these assets. For comparison, the beauty company Estee Lauder (NYSE:EL) trades at EV of 15x EBITDA according to Yahoo Finance.

Top 5 Medical Stocks To Buy Right Now: Taylor & Martin Group Inc (TMG)

Advisors’ Opinion:

  • [By Jim Cramer]

    THERMO FISHER SCIENTIFIC INC’s earnings per share improvement from the most recent quarter was slightly positive. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, THERMO FISHER SCIENTIFIC INC increased its bottom line by earning $4.70 versus $3.49 in the prior year. This year, the market expects an improvement in earnings ($7.39 versus $4.70).

     

  • [By Laurie Kulikowski]

    We rate THERMO FISHER SCIENTIFIC INC as a Buy with a ratings score of A+. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, reasonable valuation levels, good cash flow from operations and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. 

  • [By Jim Cramer]

    The stock has risen over the past year as investors have generally rewarded the company for its earnings growth and other positive factors like the ones we have cited in this report. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.

     

  • [By Jim Cramer]

    Net operating cash flow has increased to $743.90 million or 10.04% when compared to the same quarter last year. In addition, THERMO FISHER SCIENTIFIC INC has also modestly surpassed the industry average cash flow growth rate of 0.44%.

     

Leave a Reply

Your email address will not be published. Required fields are marked *